GB750373A - Improvements in or relating to injectable suspension of penicillin salts - Google Patents
Improvements in or relating to injectable suspension of penicillin saltsInfo
- Publication number
- GB750373A GB750373A GB36168/53A GB3616853A GB750373A GB 750373 A GB750373 A GB 750373A GB 36168/53 A GB36168/53 A GB 36168/53A GB 3616853 A GB3616853 A GB 3616853A GB 750373 A GB750373 A GB 750373A
- Authority
- GB
- United Kingdom
- Prior art keywords
- penicillin
- salt
- water
- diamine
- sterile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000002960 penicillins Chemical class 0.000 title abstract 4
- 229940102213 injectable suspension Drugs 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 5
- 229930182555 Penicillin Natural products 0.000 abstract 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 abstract 4
- 229940049954 penicillin Drugs 0.000 abstract 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 abstract 3
- 150000004985 diamines Chemical class 0.000 abstract 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 abstract 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- -1 alkali metal salts Chemical class 0.000 abstract 2
- 239000007864 aqueous solution Substances 0.000 abstract 2
- 230000003139 buffering effect Effects 0.000 abstract 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 abstract 2
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 abstract 2
- 231100000252 nontoxic Toxicity 0.000 abstract 2
- 230000003000 nontoxic effect Effects 0.000 abstract 2
- 150000007530 organic bases Chemical class 0.000 abstract 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 abstract 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 abstract 1
- AWBXTNNIECFIHT-XZQQZIICSA-N 2-[(1r,2r,3s,4r,5r,6s)-3-(diaminomethylideneamino)-4-[(2r,3r,4r,5s)-3-[(2s,3s,4s,5r,6s)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine;2-[(1r,2r,3s,4r,5r,6s)-3-( Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](CO)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O AWBXTNNIECFIHT-XZQQZIICSA-N 0.000 abstract 1
- GRWKNBPOGBTZMN-UHFFFAOYSA-N 2-benzyl-3-phenylpropane-1,2-diamine Chemical compound C=1C=CC=CC=1CC(N)(CN)CC1=CC=CC=C1 GRWKNBPOGBTZMN-UHFFFAOYSA-N 0.000 abstract 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 abstract 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 abstract 1
- 238000007792 addition Methods 0.000 abstract 1
- 229910052783 alkali metal Inorganic materials 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 229940088710 antibiotic agent Drugs 0.000 abstract 1
- 239000007900 aqueous suspension Substances 0.000 abstract 1
- 239000001768 carboxy methyl cellulose Substances 0.000 abstract 1
- 150000001768 cations Chemical class 0.000 abstract 1
- 229960004926 chlorobutanol Drugs 0.000 abstract 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 abstract 1
- 235000015165 citric acid Nutrition 0.000 abstract 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 abstract 1
- 239000004312 hexamethylene tetramine Substances 0.000 abstract 1
- 235000010299 hexamethylene tetramine Nutrition 0.000 abstract 1
- 235000010445 lecithin Nutrition 0.000 abstract 1
- 239000000787 lecithin Substances 0.000 abstract 1
- 229940067606 lecithin Drugs 0.000 abstract 1
- 231100000053 low toxicity Toxicity 0.000 abstract 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N m-Eugenol Chemical group COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 abstract 1
- 229960004011 methenamine Drugs 0.000 abstract 1
- 229920000609 methyl cellulose Polymers 0.000 abstract 1
- 239000001923 methylcellulose Substances 0.000 abstract 1
- 235000010981 methylcellulose Nutrition 0.000 abstract 1
- 239000001814 pectin Substances 0.000 abstract 1
- 235000010987 pectin Nutrition 0.000 abstract 1
- 229920001277 pectin Polymers 0.000 abstract 1
- 229960003742 phenol Drugs 0.000 abstract 1
- 235000011007 phosphoric acid Nutrition 0.000 abstract 1
- 150000003016 phosphoric acids Chemical class 0.000 abstract 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 abstract 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 abstract 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 229910052700 potassium Inorganic materials 0.000 abstract 1
- 239000011591 potassium Substances 0.000 abstract 1
- 239000003755 preservative agent Substances 0.000 abstract 1
- 229960004919 procaine Drugs 0.000 abstract 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 abstract 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 abstract 1
- 235000011044 succinic acid Nutrition 0.000 abstract 1
- 150000003444 succinic acids Chemical class 0.000 abstract 1
- 239000000375 suspending agent Substances 0.000 abstract 1
- 235000002906 tartaric acid Nutrition 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
- 239000000080 wetting agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
An injectable sterile aqueous suspension of a water-insoluble penicillin salt is prepared by admixing under sterile conditions a sterile, aqueous solution of a water-soluble, non-toxic salt of penicillin with a sterile, aqueous solution of a non-toxic salt of a polybasic buffering acid with an organic base which forms a water-insoluble salt with penicillin. The buffering acid is of low toxicity and forms a water-soluble salt with the cation of the water insoluble penicillin salt and examples are citric, tartaric, succinic and phosphoric acids. Specified organic bases are procaine; N, N1 dibenzylethylene diamine; N, N1 dihydroxybenylethylene diamine; N, N1 dihalobenzylethylene diamine; N, N1 di-alkoxybenzylethylene diamine; 2-chloroprocaine; and N-benzyl-N1, 3-hydroxy-4 methoxy benzyl ethylene diamine. Salts of penicillin are the alkali metal salts such as sodium and potassium and aliphatic amine salts such as triethylamine penicillin. It is preferred to have slight excess of the organic base salt. If desired the water-soluble penicillin salt may be in excess. Optional additions are (a) other antibiotics such as streptomycin and dihydro-streptomycin (b) suspending and wetting agents such as pectin, lecithin, sodium carboxy methyl cellulose, methyl cellulose, polyvinylpyrrolidone and polyoxyethylene sorbitan mono-oleate (c) preservatives such as phenol, hexamethylene tetramine, chlorobutanol and p-hydroxy-benzoic acid.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US750373XA | 1953-01-15 | 1953-01-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB750373A true GB750373A (en) | 1956-06-13 |
Family
ID=22123133
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB36168/53A Expired GB750373A (en) | 1953-01-15 | 1953-12-30 | Improvements in or relating to injectable suspension of penicillin salts |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB750373A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2273655A (en) * | 1992-12-08 | 1994-06-29 | Bimeda Res Dev Ltd | Veterinary compositions for treating mastitis |
| EP1776371A1 (en) | 2004-08-11 | 2007-04-25 | Cross Vetpharm Group Limited | A method for preparing penicillin g procaine |
| US9913905B2 (en) | 2013-09-11 | 2018-03-13 | Eagle Biologics, Inc. | Liquid pharmaceutical formulations for injection comprising thiamine pyrophosphate 1-(3-aminopropyl)-2-methyl-1H-imidazole and uses thereof |
| US11471479B2 (en) | 2014-10-01 | 2022-10-18 | Eagle Biologics, Inc. | Polysaccharide and nucleic acid formulations containing viscosity-lowering agents |
-
1953
- 1953-12-30 GB GB36168/53A patent/GB750373A/en not_active Expired
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2273655A (en) * | 1992-12-08 | 1994-06-29 | Bimeda Res Dev Ltd | Veterinary compositions for treating mastitis |
| GB2273655B (en) * | 1992-12-08 | 1997-01-08 | Bimeda Res Dev Ltd | Veterinary compositions for the treatment of mastitis |
| EP1776371A1 (en) | 2004-08-11 | 2007-04-25 | Cross Vetpharm Group Limited | A method for preparing penicillin g procaine |
| US7446194B2 (en) | 2004-08-11 | 2008-11-04 | Cross Vetpharm Limited | Preparation of penicillin procaine |
| EP1776371B1 (en) * | 2004-08-11 | 2013-07-31 | Cross Vetpharm Group Limited | A method for preparing penicillin g procaine |
| US9925263B2 (en) | 2013-09-11 | 2018-03-27 | Eagle Biologics, Inc. | Liquid pharmaceutical formulations for injection comprising procaine and uses thereof |
| US9913905B2 (en) | 2013-09-11 | 2018-03-13 | Eagle Biologics, Inc. | Liquid pharmaceutical formulations for injection comprising thiamine pyrophosphate 1-(3-aminopropyl)-2-methyl-1H-imidazole and uses thereof |
| US10179172B2 (en) | 2013-09-11 | 2019-01-15 | Eagle Biologics, Inc. | Liquid pharmaceutical formulations for injection comprising yellow 5 or orange G and uses thereof |
| US10646571B2 (en) | 2013-09-11 | 2020-05-12 | Eagle Biologics, Inc. | Liquid protein formulations containing cimetidine |
| US10821184B2 (en) | 2013-09-11 | 2020-11-03 | Eagle Biologics, Inc. | Liquid protein formulations containing thiamine pyrophosphate (TPP) |
| US10821183B2 (en) | 2013-09-11 | 2020-11-03 | Eagle Biologics, Inc. | Liquid protein formulations containing 4-(3-butyl-1-imidazolio)-1-butane sulfonate (BIM) |
| US10849977B2 (en) | 2013-09-11 | 2020-12-01 | Eagle Biologics, Inc. | Liquid Protein Formulations Containing Thiamine |
| US11819550B2 (en) | 2013-09-11 | 2023-11-21 | Eagle Biologics, Inc. | Liquid protein formulations containing cyclic adenosine monophosphate (cAMP) or adenosine triphosphate (ATP) |
| US11986526B2 (en) | 2013-09-11 | 2024-05-21 | Eagle Biologics, Inc. | Liquid protein formulations containing 4-ethyl-4-methylmorpholinium methylcarbonate (EMMC) |
| US11471479B2 (en) | 2014-10-01 | 2022-10-18 | Eagle Biologics, Inc. | Polysaccharide and nucleic acid formulations containing viscosity-lowering agents |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES468749A1 (en) | Tetracycline antibiotic compositions | |
| GB1287673A (en) | Injectable compositions | |
| MX168987B (en) | ION EXCHANGE RESINS LOADED WITH QUINOLONCARBOXYLIC ACID DERIVATIVES AND PROCEDURE FOR THEIR OBTAINING | |
| GB750373A (en) | Improvements in or relating to injectable suspension of penicillin salts | |
| ES396215A1 (en) | N-(1-bicyclic aryl-propyl-2)-n'-bicyclic aryl-piperazines | |
| ES388141A1 (en) | PROCEDURE FOR OBTAINING REGULATORY COMPOSITIONS OF PLANT GROWTH. | |
| GB705343A (en) | Improvements in or relating to aqueous suspensions of procaine penicillin | |
| GB1304137A (en) | ||
| GB816592A (en) | A method for the preparation of stable magnesium solutions of high concentration | |
| GB757137A (en) | New adrenochrome derivative and process for its production | |
| GB901675A (en) | Process for improving the storage qualities of conserved whole-blood | |
| ES336572A1 (en) | Benzodioxane derivatives of guanidine | |
| ES249787A1 (en) | Improvements in or relating to phenothiazine derivatives | |
| GR17671B (en) | MINERAL DERIVATIVES OF THIOCARBIMIC ACIDS. | |
| GB544836A (en) | Improvements relating to the preparation of sulphonamide compounds | |
| GB772322A (en) | Improvements in stabilized aqueous hyaluronidase solutions | |
| GB684459A (en) | A stable aqueous solution of dihydrostreptomycin and method of preparing same | |
| ES404794A1 (en) | A PROCEDURE FOR THE PREPARATION OF NEW XANTONE-CARBOXYL ACID COMPOUNDS REPLACED WITH A HETEROCICLE. | |
| GB798680A (en) | Improvements in or relating to the preparation of pharmaceutical compositions | |
| SE7606795L (en) | WAY TO PREPARE A NEW DESOXISTREPTAMIN DERIVATIVE AND ITS SALTS | |
| GB778148A (en) | Stable neomycin compositions for oral administration | |
| ES224139A1 (en) | A procedure to improve the ease of new suspension of aqueous penicilline suspensions (Machine-translation by Google Translate, not legally binding) | |
| GB708405A (en) | Sterile aqueous suspensions of procaine penicillin | |
| GB862537A (en) | Anti-microbial compositions | |
| GB755997A (en) | Improvements in or relating to pyrimidine derivatives |